529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study

Background

Ramucirumab (RAM) plus docetaxel (DOC) combination therapy is one of the standard treatment options for second-line in patients with advanced NSCLC. Previous studies reported that history of pre-administration of immune checkpoint inhibitors was related to good outcomes with RAM plus DOC. However, the clinical significance of RAM plus DOC after combined immunotherapy is little known. Therefore, we evaluated RAM plus DOC after combined chemoimmunotherapy and attempted to identify predictors for their outcomes.

Methods

This multicenter prospective study aimed to investigate the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). The secondary endpoints are objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events (AEs). Serum cytokines at the start of treatment were measured as an exploratory investigation.

Results

A total of 44 patients were enrolled, at 10 Japanese institutions from November 2019 and March 2021. The median PFS was 6.3 months (95% confidence interval [CI]: 4.2–8.8), and the median OS was 22.6 months (95% CI: 13.9–NE). The ORR and DCR were 36.4% (95% CI: 22.4–52.2) and 72.7% (95% CI: 57.2–85.0). High VEGF-D groups had significantly shortened PFS and OS. The combination of high VEGF-A and low VEGF-D had a longer PFS than other groups.

Conclusions

The primary endpoint was met; RAM plus DOC after combined chemoimmunotherapy is an effective and relatively feasible second-line treatment in patients with advanced NSCLC in the real-world setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

T. Yamada, K. Takayama: Financial Interests, Personal, Invited Speaker: Eli Lilly. All other authors have declared no conflicts of interest.